Defensive Puts vs. Bull Calls: Options Clash
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Earnings season is driving a stark split in the options market. Bulls and bears are staking opposite positions ahead of key prints, with the clearest divergence in insurance and homebuilding.
The Hanover Insurance Group is the most striking case. The insurer's options flow turned 100% positive over the past seven days, even as a headline from ORTEX News flagged options positioning had "turned sharply defensive" before its Q3 print. The contradiction matters: count-based flow skews bullish, but dollar-weighted bets tell a different story. THG is up 29% year-to-date, giving put buyers something to protect.
Green Brick Partners sits on the other side. Call-side activity heated up ahead of its Q3 print, per ORTEX data. GRBK carries a short score of 58 and a days-to-cover of nearly 13. That combination makes any bullish options move notable. A squeeze is possible if results surprise.
Across larger names, the 7-day options score pointed highest at The Cigna Group. Cigna also has an upcoming Q3 earnings event, adding event-driven urgency to the positioning.
On the macro side, Amazon and Apple both carry option chains running out to January 2027. The density of near-term expiries, with AMZN showing 12 distinct dates before year-end, reflects high demand for short-dated hedges around their upcoming results.
The index rebalance clock also adds pressure. Twist Bioscience's Russell 1000 addition probability jumped from 20% to 55% overnight, per ORTEX Index Rebalance Radar. The 30 October cut-off is today. A confirmed addition would force $529M of buying, making it a live options catalyst.
Stocks in this article
How this article was generated
- Generated
- 29 Oct 2026, 04:42
- Prompt version
- v1.0
- Data sources
- Options flowORTEX Alpha signalsAlt DataIndex Rebalance
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.